Literature DB >> 27910004

Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.

Mariagrazia Porru1, Antonella Mameli2, Maria E Cianchetti1, Mario Musu3, Paola Schirru1, Maria F Ruberto1, Doris Barcellona1, Francesco Marongiu1.   

Abstract

Dabigatran is an oral, direct thrombin inhibitor approved by international regulatory agencies for stroke prevention in patients with paroxysmal or persistent non-rheumatic atrial fibrillation (AF). The benefits of dabigatran are widely described, but its use in the geriatric population is not without risk. Chronic kidney disease is a common comorbidity with AF, and thus frequent checks of renal function in elderly patients are recommended. We report a case of dabigatran intoxication in an elderly man affected by heart failure and worsening renal function, who developed acute hepatitis and coma, which was successfully treated with continuous veno-venous hemodiafiltration. Although extracorporeal therapy has been suggested as a strategy for clearing dabigatran during acute bleeding, this approach may be useful in other dabigatran-related, life-threatening conditions, such as that described in this report.

Entities:  

Keywords:  Acute hepatitis; Continuous veno-venous hemodiafiltration; Dabigatran etexilate; Overdose

Mesh:

Substances:

Year:  2016        PMID: 27910004     DOI: 10.1007/s12185-016-2158-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  13 in total

1.  Comparison of intermittent and continuous extracorporeal treatments for the enhanced elimination of dabigatran.

Authors:  Josée Bouchard; Marc Ghannoum; Amélie Bernier-Jean; David Williamson; Geoffrey Kershaw; Claire Weatherburn; Josette M Eris; Huyen Tran; Jignesh P Patel; Darren M Roberts
Journal:  Clin Toxicol (Phila)       Date:  2015-02-08       Impact factor: 4.467

2.  Removal of Dabigatran Is Superior by Sustained Low Efficient Dialysis (SLED) Compared to Intermittent Hemodialysis.

Authors:  Ferruh Artunc; Thomas Muehlbacher; Dorothea Baumann; Ingvild Birschmann; Joachim Kuhn; Nils Heyne; Andreas Peter
Journal:  Blood Purif       Date:  2015-05-14       Impact factor: 2.614

3.  Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

Authors:  T Baglin; A Hillarp; A Tripodi; I Elalamy; H Buller; W Ageno
Journal:  J Thromb Haemost       Date:  2013-01-24       Impact factor: 5.824

Review 4.  Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors:  Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal:  Thromb Haemost       Date:  2010-03-29       Impact factor: 5.249

5.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

6.  European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation.

Authors:  Hein Heidbuchel; Peter Verhamme; Marco Alings; Matthias Antz; Werner Hacke; Jonas Oldgren; Peter Sinnaeve; A John Camm; Paulus Kirchhof
Journal:  Europace       Date:  2013-05       Impact factor: 5.214

7.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

8.  Removal of dabigatran by hemodialysis.

Authors:  Don N Chang; William E Dager; Andrew I Chin
Journal:  Am J Kidney Dis       Date:  2012-12-05       Impact factor: 8.860

9.  The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.

Authors:  Stefan Blech; Thomas Ebner; Eva Ludwig-Schwellinger; Joachim Stangier; Willy Roth
Journal:  Drug Metab Dispos       Date:  2007-11-15       Impact factor: 3.922

10.  Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit.

Authors:  Guillaume Claisse; Xavier Delavenne; Ingrid Masson; Nicolas Maillard; Eric Alamartine; Christophe Mariat
Journal:  Clin Kidney J       Date:  2015-01-24
View more
  2 in total

1.  Re. Re. Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment and review of the literature.

Authors:  Mariagrazia Porru; Antonella Mameli; Maria Elisabetta Cianchetti; Filomena Ruberto; Mario Musu; Doris Barcellona; Francesco Marongiu
Journal:  Int J Hematol       Date:  2018-07-03       Impact factor: 2.490

2.  Re: Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.

Authors:  Kelsea Caruso; Michele Kanter
Journal:  Int J Hematol       Date:  2018-02-08       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.